Nebulin (Budesonide)

Nebulin (budesonide) is used in the respiratory therapeutic area to reduce airway inflammation and improve breathing function.

• Asthma: helps control chronic inflammation, reduces frequency of exacerbations, and improves lung function.
• Chronic obstructive pulmonary disease (COPD): decreases airway inflammation, lessens symptom severity, and reduces risk of flare‑ups.
• Chronic bronchitis (as part of COPD): alleviates cough and sputum production by targeting inflammatory pathways in the bronchial mucosa.

• Budesonide penetrates airway cells and binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus. This complex interacts with glucocorticoid response elements, modulating gene transcription to suppress pro‑inflammatory cytokines, inhibit leukocyte recruitment, and reduce airway edema, thereby decreasing airway hyper‑responsiveness and improving airflow.

Adverse reactions may occur with inhaled budesonide. Patients should be aware of both common and less frequent events.

Common Side Effects

• Oral thrush: fungal infection of the mouth and throat.
• Hoarseness or dysphonia: voice changes after inhalation.
• Cough or throat irritation: irritation of the upper airway.
• Headache: mild to moderate head discomfort.

Serious or Rare Side Effects

• Adrenal suppression: reduced cortisol production with prolonged high‑dose use.
• Pneumonia: increased risk in patients with underlying lung disease.
• Paradoxical bronchospasm: sudden worsening of breathing after inhalation.
• Ocular effects: cataracts or glaucoma with long‑term therapy.

Nebulin should be used with attention to specific safety considerations.

• Infection risk: assess for active respiratory infections before initiating therapy.
• Growth monitoring: regularly evaluate growth in pediatric patients receiving long‑term treatment.
• Oral hygiene: rinse mouth with water after each inhalation to reduce local fungal growth.
• Discontinuation: avoid abrupt cessation; taper dose under medical supervision if high‑dose therapy has been used.
• Store at room temperature: keep in the original container, protect from moisture and direct heat.

Budesonide may interact with other medicines that affect its metabolism or enhance systemic corticosteroid effects.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir): may increase systemic exposure.
• Systemic corticosteroids: additive immunosuppressive effects.
• Antifungal agents (e.g., posaconazole) that inhibit glucocorticoid metabolism.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
• Diuretics: potential for hypokalemia when combined with systemic steroids.